donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NVS Novartis AG > Detailed Quotes

NVS Novartis AG

85.720
+0.140+0.16%
Trading Session 08/12 13:45 ET
High
85.825
Open
85.060
Turnover
162.70M
Low
84.680
Pre Close
85.580
Volume
1.91M
Market Cap
187.11B
P/E(TTM)
8.40
52wk High
94.260
Shares
2.18B
P/E(Static)
8.06
52wk Low
76.151
Float Cap
184.31B
Bid/Ask %
14.29%
Historical High
94.260
Shs Float
2.15B
Volume Ratio
1.60
Historical Low
9.771
Dividend TTM
3.325
Div Yield TTM
2400
P/B
2.97
Dividend LFY
3.88%
Div Yield LFY
2799.81%
Turnover Ratio
0.09%
Amplitude
1.34%
Avg Price
85.176
Lot Size
1
Float Cap
184.31B
Bid/Ask %
14.29%
Historical High
94.260
Shs Float
2.15B
Volume Ratio
1.60
Historical Low
9.771
Dividend TTM
3.325
P/B
2.97
Dividend LFY
3.88%
Turnover Ratio
0.09%
Amplitude
1.34%
Avg Price
85.176
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
CEO: Birch, Neil William
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...